Targeted molecular therapy for neuroblastoma: The ARF/MDM2/p53 Axis

Journal of the National Cancer Institute

Volumn 101, Issue 22, 2009, Pages 1527-1529

  Shohet, Jason ^a   Kim, Eugene ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARF PROTEIN; DOXORUBICIN; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURGERY; DRUG MEGADOSE; EDITORIAL; GENOTOXICITY; HIGH RISK PATIENT; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR THERAPY; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR RESISTANCE; TUMOR XENOGRAFT; WILD TYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; IMIDAZOLES; MICE; MICE, TRANSGENIC; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-MDM2; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 72949107687     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp376     Document Type: Editorial

References (36)

1. Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin North Am. 2008 ; 55 (1): 97-120.
2. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol. 2009 ; 27 (7): 1007-1013.
3. Van Maerken T, Ferdinande L, Taildeman J, et al. Antitumor activity of the selective MDM2 antagonist Nutlin-3 against chemoresistant neuroblastoma with wild-type p53. J Natl Cancer Inst. 2009 ; 101 ;(22): 1562-1574.
4. Chen L, Malcolm AJ, Wood KM, et al. p53 is nuclear and functional in both undifferentiated and differentiated neuroblastoma. Cell Cycle. 2007 ; 6 (21): 2685-2696.
5. Lestini BJ, Goldsmith KC, Fluchel MN, et al. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther. 2009 ; 8 (16): 1550-1558.
6. Islam A, Kageyama H, Takada N, et al. High expression of survivin, mapped to 17q25, is signifi cantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000 ; 19 (5): 617-623.
7. Chesler L, Goldenberg DD, Collins R, et al. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia. 2008 ; 10 (11): 1268-1274.
8. Barbieri E, Mehta P, Chen Z, et al. MDM2 inhibition sensitizes neuro-blastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther. 2006 ; 5 (9): 2358-2365.
9. Vogan K, Bernstein M, Leclerc JM, et al. Absence of p53 gene mutations in primary neuroblastomas. Cancer Res. 1993 ; 53 (21): 5269-5273.
10. Meek DW. Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer. 2009 ; 9 (10): 712-723.
11. Hainaut P, Wiman KG. 30 years and a long way into p53 research. Lancet Oncol. 2009 ; 10 (9): 913-919.
12. Singh RK, Iyappan S, Scheffner M. Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING fi nger mutants of Mdm2. J Biol Chem. 2007 ; 282 (15): 10901-10907.
13. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer. 2006; 6 (9): 663-673.
14. Marine JC, Lozano G. Mdm2-mediated ubiquitylation: p53 and beyond. [published online ahead of print June 5, 2009]. Cell Death Differ. p. 1-10.
15. Kruse JP, Gu W. Modes of p53 regulation. Cell. 2009 ; 137 (4): 609-622.
16. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med. 2007; 13 (1): 23-31.
17. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004 ; 303 (5659): 844-848.
18. Hansford LM, Thomas WD, Keating JM, et al. Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplifi-cation. Proc Natl Acad Sci U S A. 2004 ; 101 (34): 12664-12669.
19. Grimmer MR, Weiss WA. Childhood tumors of the nervous system as disorders of normal development. Curr Opin Pediatr. 2006 ; 18 (6): 634-638.
20. De Zio D, Giunta L, Corvaro M, Ferraro E, Cecconi F. Expanding roles of programmed cell death in mammalian neurodevelopment. Semin Cell Dev Biol. 2005 ; 16 (2): 281-294.
21. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res. 2007 ; 67 (2): 735-745.
22. Alam G, Cui H, Shi H, et al. MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development. Am J Pathol. 2009 ; 175 (2): 856-866.
23. Chen Z, Lin Y, Barbieri E, et al. Mdm2 defi ciency suppresses MYCN-driven neuroblastoma tumorigenesis in vivo. Neoplasia. 2009 ; 11 (8): 753-762.
24. Alt JR, Greiner TC, Cleveland JL, Eischen CM. Mdm2 haplo-insuffi ciency profoundly inhibits Myc-induced lymphomagenesis. EMBO J. 2003 ; 22 (6): 1442-1450.
25. Wang P, Greiner TC, Lushnikova T, Eischen CM. Decreased Mdm2 expression inhibits tumor development induced by loss of ARF. Oncogene. 2006 ; 25 (26): 3708-3718.
26. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacety-lases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med. 2005 ; 11 (1): 71-76.
27. Uo T, Veenstra TD, Morrison RS. Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms. J Neurosci. 2009 ; 29 (9): 2824-2832.
28. Kojima K, Shimanuki M, Shikami M, et al. The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia. 2008 ; 22 (9): 1728-1736.
29. Kojima K, Konopleva M, Tsao T, Nakakuma H, Andreeff M. Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood. 2008 ; 112 (7): 2886-2895.
30. Joseph JM, Gross N, Lassau N, et al. In vivo echographic evidence of tumoral vascularization and microenvironment interactions in metastatic orthotopic human neuroblastoma xenografts. Int J Cancer. 2005 ; 113 (6): 881-890.
31. Meier R, Muhlethaler-Mottet A, Flahaut M, et al. The chemokine receptor CXCR4 strongly promotes neuroblastoma primary tumour and metastatic growth, but not invasion. PLoS One. 2007 ; 2 (10): e1016.
32. Carr J, Bell E, Pearson AD, et al. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res. 2006 ; 66 (4): 2138-2145.
33. Nowak K, Kerl K, Fehr D, et al. BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res. 2006 ; 34 (6): 1745-1754.
34. Valsesia-Wittmann S, Magdeleine M, Dupasquier S, et al. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell. 2004 ; 6 (6): 625-630.
35. Tweddle DA, Pearson AD, Haber M, et al. The p53 pathway and its inac-tivation in neuroblastoma. Cancer Lett. 2003 ; 197 (1-2): 93-98.
36. Laverdiere C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2009 ; 101 (16): 1131-1140